Skip to main content
. 2010 Mar 31;17(9):2518–2525. doi: 10.1245/s10434-010-1038-8

Table 3.

Number of HCC patients at different stages identified by serum SELDI-TOF-MS pattern and AFP20

Tumor stage Number of patients SELDI-TOF-MS pattern (n/%) AFP20 (n/%)
I 46 40/87% 25/54%*
II 36 32/89% 26/72%
III 38 37/97% 32/84%
Total 120 109/91% 83/69%

Note: AFP20, at a cutoff value >20 ng/mL

* Compared with SELDI-TOF-MS, P < .05